Baystreet Staff -

Hemispherx Biopharma, Inc. Discusses Clinical Development and Approval in Argentina in New SNNLive Video Interview on StockNewsNow.com

[ACCESSWIRE]

LOS ANGELES, CA / ACCESSWIRE / January 3, 2018 / StockNewsNow.com, The Official MicroCap News Source™, today published an SNNLive Video Interview with Thomas Equels, CEO of Hemispherx Biopharma, Inc. (NYSE American: HEB), an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders, according to the company's website (see here: www.hemispherx.net). The video interview was recorded on Tuesday, December 5th, 2017 at the LD Micro "Main Event" 2017 in Bel Air, CA.

Click the following link to watch the SNNLive Video Interview on StockNewsNow.com:

Hemispherx Biopharma, Inc. – Advanced Specialty Pharmaceutical Company Discusses Clinical Development and Approval in Argentina

You can follow Stock News Now on FACEBOOK, TWITTER, LINKEDIN, YOUTUBE, and STOCKTWITS

Please review important disclosures on our website at: http://stocknewsnow.com/legal.php#disclaimer

About Hemispherx Biopharma, Inc.

Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection® and the experimental therapeutic rintatolimod (tradenames Ampligen® or Rintamod®). Rintatolimod is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Hemispherx's platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Because rintatolimod is experimental in nature, it is not designated safe and effective by the FDA for general use and is legally available only through clinical trials.

For more information about Hemispherx Biopharma, Inc., please visit: www.hemispherx.net

About StockNewsNow.com

StockNewsNow.com is a microcap financial news portal that features news and insights from the microcap and emerging growth financial community. StockNewsNow.com is a multimedia destination hub for information about microcap and emerging growth public and private companies, market events, news, bulletins, stock quotes, expert commentary and company profiles that feature SNN-produced video like SNNLive CEO video interviews, as well as their latest news and headlines. Users can engage directly and share the information provided through social media.

Follow the companies YOU want to know more about; read and watch content from YOUR favorite microcap, emerging growth financial experts; register to attend financial conferences of YOUR choosing; find microcap and emerging growth financial professionals that YOU may be looking for - all here on StockNewsNow.com.

info@stocknewsnow.com

SOURCE: StockNewsNow.com